Globe News Wire
28 May 2026, 05:30 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/28/3302504/0/en/new-late-breaking-data-reinforces-iqirvo-s-impact-on-alp-fatigue-and-pruritus-in-pbc.html
Read source
Search tags
Story key points
3 claims · impact-rated
Post hoc analysis of the Phase III ELATIVE trial shows IQIRVO significantly improved fatigue in 67% of patients compared to 31% for placebo. — Clinical evidence of symptom improvement (fatigue) addresses a major unmet need and increases the drug's competitive value and market adoption.
+0.60U.S. real-world data indicates 59% of patients achieved ALP normalization, a key marker for slowing disease progression in PBC. — Real-world evidence confirming biochemical goals (ALP normalization) supports the drug's long-term efficacy and physician confidence.
+0.50Interim Phase IV ELFINITY study results showed 55% of patients achieved biochemical response within three months with no serious adverse events. — Confirmation of safety and rapid onset of action in routine clinical practice reduces the risk of future regulatory or safety-related setbacks.
+0.40Ticker attribution
Model heads
The company announced positive late-breaking Phase III and real-world data showing significant efficacy of its drug IQIRVO in treating PBC.
No ticker relationship head found.
Impact vectors
6 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
